Company GENFIT Other OTC

Equities

GNFTF

FR0004163111

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.

The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

EUR in Million	2022	Weight	2023	Weight	Delta
Research and Development of Innovative Medicines and Diagnostic Solutions 100.0 %	20	100.0 %	29	100.0 %	+41.45%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	20	100.0 %	29	100.0 %	+41.45%

Managers	Title	Age	Since
Pascal Prigent CEO	Chief Executive Officer	56	30/04/18
Jean-François Mouney FOU	Founder	68	31/08/99
Thomas Baetz DFI	Director of Finance/CFO	50	21/04/21
John Brozek CTO	Chief Tech/Sci/R&D Officer	47	-
Stefanie Magner CMP	Compliance Officer	43	31/12/15
Pascal Caisey COO	Chief Operating Officer	56	31/08/19
Carol L. Addy CTO	Chief Tech/Sci/R&D Officer	64	08/09/19
Meriam Kabbaj CTO	Chief Tech/Sci/R&D Officer	50	30/11/22
Dean Hum CTO	Chief Tech/Sci/R&D Officer	61	31/12/99
Jean-Christophe Marcoux IRC	Investor Relations Contact	47	31/12/14

Members of the board	Title	Age	Since
Jean-François Tiné BRD	Director/Board Member	67	03/03/21
Jean-François Mouney FOU	Founder	68	31/08/99
Florence Séjourné FOU	Founder	52	14/09/99
Xavier Guille des Buttes BRD	Director/Board Member	82	17/10/06
Catherine Larue BRD	Director/Board Member	68	15/06/17
Anne-Hélène Monsellato BRD	Director/Board Member	56	15/06/17
Katherine Kalin BRD	Director/Board Member	61	06/07/20
Eric Baclet BRD	Director/Board Member	64	06/07/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,834,983	43,240,391 ( 86.77 %)	0	86.77 %

Name	Equities	%	Valuation
IPSEN 7.992 %	3,985,239	7.992 %	20 M $
Tang Capital Management LLC 4.914 %	2,450,404	4.914 %	13 M $
Biotech Avenir SAS 3.788 %	1,888,618	3.788 %	10 M $
Universite de Lille II Foundation 1.306 %	651,250	1.306 %	3 M $
Sunny Asset Management SA 0.2407 %	120,000	0.2407 %	614 884 $
Mandarine Gestion SA 0.1302 %	64,911	0.1302 %	332 606 $
Jean-François Mouney 0.0934 %	46,594	0.0934 %	238 749 $
OFI Invest Asset Management SA 0.0624 %	31,128	0.0624 %	159 501 $
Pascal Prigent 0.0616 %	30,708	0.0616 %	157 349 $
Clay Asset Management SAS 0.0602 %	30,000	0.0602 %	153 721 $

Name	Equities	%	Valuation
Millennium Management LLC 0.0596 %	29,717	0.0596 %	153 934 $
Morgan Stanley & Co. International Plc 0.0571 %	28,464	0.0571 %	147 444 $
Citadel Securities GP LLC 0.0338 %	16,833	0.0338 %	87 195 $
Optiver Holding BV 0.001931 %	963	0.001931 %	4 988 $
RhumbLine Advisers LP 0.001360 %	678	0.001360 %	3 512 $
Qube Research & Technologies Ltd. (France) 0.000197 %	98	0.000197 %	508 $

Genfit SA

Parc Eurasante 885, Avenue Eugène Avinée

59120, Loos

+33 3 20 16 40 00

http://www.genfit.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+20.86%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.14%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.25%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.72%	25.88B
MEDPACE HOLDINGS, INC.	+36.29%	12.53B
BIO-TECHNE CORPORATION	-6.98%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.53%	10.65B

Other Biotechnology & Medical Research